A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Recruiting now · Phase 2

Conditions studied: Proteinuric Kidney Disease

In brief

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Key facts

Study ID
NCT06830629
Run by
Maze Therapeutics
People needed
74
Starts
2025-02-05
Expected to finish
2026-09-01
Last updated by the study team
2026-07-27

Who can join

Age: 18 and older, up to 68. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.